

Rec'd PTO

22 DEC 2005

10/532618

#4

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 12/20/05 Signature: Janice Roussel

(Janice Roussel)

Docket No.: 0113873.00124US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Dov TAMARKIN et al.

Application No.: 10/532618

Confirmation No.: 9411

Filed: April 25, 2005

Art Unit: 1614

For: COSMETIC AND PHARMACEUTICAL
FOAM

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: December 20, 2005 Respectfully submitted,

By Mary Rose Scozzafava
Mary Rose Scozzafava
Registration No.: 36,268
WILMER CUTLER PICKERING HALE AND
DORR LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000
Attorney for Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/532618-Conf. #9411
				Filing Date	April 25, 2005
				First Named Inventor	Dov TAMARKIN
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	0113873.00124US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
AA*	US-2002/0035046		03-21-2002	Lukenbach et al.	
AB*	US-2002/0072544		06-13-2002	Miller et al.	
AC*	US-2002/0098215		07-25-2002	Douin et al.	
AD*	US-2004/0151671		08-05-2004	Abram et al.	
AE*	US-2004/0265240		12-30-2004	Tamarkin et al.	
AF*	US-2005/0031547		02-10-2005	Tamarkin et al.	
AG*	US-2005/0069566		03-31-2005	Tamarkin et al.	
AH*	US-2005/0074414		04-07-2005	Tamarkin et al.	
AI*	US-2005/0075407		04-07-2005	Tamarkin et al.	
AJ*	US-2005/0079139		04-14-2005	Jacques et al.	
AK*	US-2005/0186142-A1		08-25-2005	Tamarkin et al.	
AL*	US-2005/0186147-A1		08-25-2005	Tamarkin et al.	
AM*	US-2005/0205086-A1		09-22-2005	Tamarkin et al.	
AN*	US-3,912,665		10-14-1975	Spitzer et al.	
AO*	US-4,145,411		03-20-1979	Mende	
AP*	US-4,271,149		06-02-1981	Winicov et al.	
AQ*	US-4,529,601		07-16-1985	Broberg et al.	
AR*	US-4,808,388		02-28-1989	Beutler et al.	
AS*	US-4,837,378		06-06-1989	Borgman	
AT*	US-4,874,794		10-17-1989	Katz	
AU*	US-4,981,677		01-01-1991	Thau	
AV*	US-5,002,680		03-26-1991	Schmidt et al.	
AW*	US-5,034,220		07-23-1991	Helioff et al.	
AX*	US-5,071,648		12-10-1991	Rosenblatt	
AY*	US-5,143,717		09-01-1992	Davis	
AZ*	US-5,171,577		12-15-1992	Griat et al.	
AA1*	US-5,254,334		10-19-1993	Ramirez et al.	
AB1*	US-5,262,407		11-16-1993	Leveque et al.	
AC1*	US-5,326,557		07-05-1994	Glover et al.	
AD1*	US-5,411,992		05-02-1995	Eini et al.	
AE1*	US-5,435,996		07-25-1995	Glover et al.	
AF1*	US-5,534,261		07-09-1996	Rodgers et al.	
AG1*	US-5,536,743		07-16-1996	Borgman	
AH1*	US-5,545,401		08-13-1996	Shanbrom	
AI1*	US-5,589,515		12-31-1996	Suzuki et al.	
AJ1*	US-5,635,469		06-03-1997	Fowler et al.	
AK1*	US-5,641,480		06-24-1997	Vermeer, R.	
AL1*	US-5,672,634		09-30-1997	Tseng et al.	
AM1*	US-5,679,324		10-21-1997	Lisboa et al.	
AN1*	US-5,700,396		12-23-1997	Suzuki et al.	
AO1*	US-5,716,611		02-10-1998	Oshlack et al.	
AP1*	US-5,759,520		06-02-1998	Sachetto	
AQ1*	US-5,783,202		07-21-1998	Tomlinson et al.	
AR1*	US-5,840,744		11-24-1998	Borgman	
AS1*	US-5,922,331		07-13-1999	Mausner	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	3	Application Number	10/532618-Conf. #9411
				Filing Date	April 25, 2005
				First Named Inventor	Dov TAMARKIN
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	0113873.00124US2

AT1*	US-5,951,993	09-14-1999	Scholz et al.	
AU1*	US-5,961,957	10-05-1999	McAnalley	
AV1*	US-5,972,310	10-26-1999	Sachetto	
AW1*	US-5,993,846	11-30-1999	Friedman et al.	
AX1*	US-6,093,408	07-25-2000	Hasenoehrl et al.	
AY1*	US-6,113,888	09-05-2000	Castro et al.	
AZ1*	US-6,121,210	09-19-2000	Taylor	
AA2*	US-6,126,920	10-03-2000	Jones et al.	
AB2*	US-6,187,290	02-13-2001	Gilchrist et al.	
AC2*	US-6,251,369	06-26-2001	Stoltz	
AD2*	US-6,258,374	07-10-2001	Friess et al.	
AE2*	US-6,333,362	12-25-2001	Lorant	
AF2*	US-6,358,541	03-19-2002	Goodman	
AG2*	US-6,383,471-B1	05-07-2002	Chen et al.	
AH2*	US-6,410,036	06-25-2002	De Rosa et al.	
AI2*	US-6,423,323-B1	07-23-2002	Neubourg	
AJ2*	US-6,468,989-B1	10-22-2002	Chang et al.	
AK2*	US-6,524,594	02-25-2003	Santora et al.	
AL2*	US-6,536,629	03-25-2003	van der Heijden	
AM2*	US-6,544,530	04-08-2003	Friedman	
AN2*	US-6,620,773	09-16-2003	Stork et al.	
AO2*	US-6,730,288-B1	05-04-2004	Abram	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
BI	EP-0270316		08-06-1988	Pfizer, Inc.	
BQ	EP-0488089-A1		06-03-1992	Kali-Chemie Pharma GmbH	
BE	EP-0535327		07-04-1993	American Cyanamid Co.	
BK	EP-0598412		11-19-1993	Medicon Gesellschaft	
BP	EP-1055425-A2		11-29-2000	Bristol-Myers Squibb Co.	
BC	IL-0152486-A0		05-29-2003	Eini	
BJ	JP-2002012513		01-15-2002	Fumiko	
BA	WO-00/15193		03-23-2000	Soltec Research Pty. Ltd.	
BN	WO-01/70242-A2		09-27-2001	Ben Gurion Univ.	
BH	WO-02/00820		01-03-2002	Combe International Ltd.	
BG	WO-02/41847-A1		05-30-2002	Wella Aktiengesellschaft	
BO	WO-03/051294		06-26-2003	Medicis Pharmaceuti	
BF	WO-03/053292		07-03-2003	Femmepharma, Inc.	
BD	WO-04/112780		12-29-2004	Gal-Derma Research	
BL	WO-91/11991		08-22-1991	Kabi Pharmacia	
BM	WO-96/19921		04-07-1996	Commonwealth Scie	
BB	WO-96/27376		09-12-1996	Medeva PLC	

Examiner Signature		Date Considered
--------------------	--	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	10/532618-Conf. #9411
				Filing Date	April 25, 2005
				First Named Inventor	Dov TAMARKIN
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	0113873.00124US2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	BARRY, B.W. et al, Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments, British Journal of Dermatology, 93, 563-571, 1975.		T ²
	CB	MARTINDALE, The extra pharmacopoeia [28th] edition, Eds.: Reynolds, J.E.F. and Prasad, A.B., The Pharmaceutical Press, London, pp. 862-864, 1982.		
	CC	TAMARKIN, D., et al. Body Cavity Foam, U.S. Appl. No. 11/116761, filed 04/28/2005.		
	CD	TAMARKIN, D., et al. Moisturizing Foam Containing Lanolin, U.S. Appl. No. 11/099942, filed 04/06/2005.		
	CE	TAMARKIN, D., et al. Nonsteroidal Immunomodulating Kit and Composition and Uses Thereof, U.S. Appl. No. 11/078902, filed 03/11/2005.		
	CF	TAMARKIN, D., et al. Steroid Kit and Foamable Composition and Uses, U.S. Appl. No. 11/114410, filed 04/26/2005.		
	CG	TAMARKIN, D., et al. Vasoactive Kit and Composition and Uses Thereof, U.S. Appl. No. 11/124676, filed 05/09/2005.		
	CH	WORMSER et al. Arch. Toxicol., 71, 165-170, 1997.		
	CI	WORMSER et al. Letters to the Editor, Burns, 24, 383, 1998.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------